Table 1

 Characteristics of the four extensively reviewed rheumatoid arthritis trials using ⩽10 mg prednisone daily

StudyARC studyLDPT studyUtrecht studyWOSERACT
DMARDs, disease modifying antirheumatic drugs; IM, intramuscular; MTX, methotrexate.
Year of first publication1995200020022004
Reference1, 2345
RA duration at entry (years)<2<2<1Median 1
Number of patients,
>prednisolone group
Prednisolone dose/day (mg)7.55107
Duration of trial (years)2222
Associated DMARDsVariousIM gold or MTXSulfasalazine rescueSulfasalazine